TP53 mutations have been reported mutually exclusive with NPM1 mutation and FLT3–ITD,43, 44, 45 underscoring the probability for AVA sensitivity in AML patients with NPM1 and FLT3–ITD. This evidence concerns the gene TP53 and acute myeloid leukemia.